Magnetar Financial LLC Grows Stock Position in DENTSPLY SIRONA Inc. $XRAY

Magnetar Financial LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 539.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 205,549 shares of the medical instruments supplier’s stock after buying an additional 173,428 shares during the quarter. Magnetar Financial LLC owned 0.10% of DENTSPLY SIRONA worth $2,608,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its holdings in DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares during the last quarter. Norges Bank purchased a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth $39,700,000. Goldman Sachs Group Inc. grew its position in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares during the period. Brickwood Asset Management LLP increased its stake in shares of DENTSPLY SIRONA by 5,515.8% in the 3rd quarter. Brickwood Asset Management LLP now owns 1,524,074 shares of the medical instruments supplier’s stock worth $19,340,000 after purchasing an additional 1,496,935 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of DENTSPLY SIRONA by 1,163.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,252,372 shares of the medical instruments supplier’s stock worth $15,893,000 after purchasing an additional 1,153,271 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Gregory T. Lucier purchased 15,000 shares of DENTSPLY SIRONA stock in a transaction on Monday, March 9th. The shares were bought at an average cost of $12.45 per share, for a total transaction of $186,750.00. Following the acquisition, the director owned 65,000 shares in the company, valued at approximately $809,250. The trade was a 30.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James D. Forbes purchased 5,000 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was bought at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the purchase, the director owned 10,000 shares in the company, valued at approximately $124,800. This represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have acquired 70,000 shares of company stock valued at $956,437. Insiders own 0.50% of the company’s stock.

DENTSPLY SIRONA Stock Performance

NASDAQ XRAY opened at $11.80 on Friday. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of -3.93, a price-to-earnings-growth ratio of 1.49 and a beta of 0.97. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. The business has a 50-day moving average price of $12.72 and a 200-day moving average price of $12.43. DENTSPLY SIRONA Inc. has a twelve month low of $9.85 and a twelve month high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. During the same period last year, the business posted $0.26 EPS. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts predict that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

XRAY has been the subject of several recent research reports. Wells Fargo & Company boosted their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Barrington Research raised their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Barclays initiated coverage on DENTSPLY SIRONA in a research note on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective for the company. Robert W. Baird increased their target price on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Finally, Mizuho raised their target price on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $14.42.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.